Skip to content

SAMHD1 Research Digest β€” 2026-07-19

Generated by samhd1_monitor | Model: claude-sonnet-5

Summary: 7 papers evaluated | 0 high-relevance (β‰₯7) | 3 medium (5–6) | 4 low (3–4) | 0 scored <3

🟑 Medium Relevance (Score 5–6)

Score β‰₯6 auto-added to Zotero; lower scores: review manually

Chirality-dependent toxicity decoupling: Discovery of a resibufogenin-based L-configured STING inhibitor with superior therapeutic profile for ulcerative colitis. (from medicinal chemistry/gastroenterology (ulcerative colitis drug discovery))
Zhuang Jia-Hua; Zhang Qiu-Heng; Zhou Si-Yu; Wen Yuting; Li Yiming β€” European journal of medicinal chemistry 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target

Novel STING inhibitor targeting the STING-TBK1-IRF3-IL-1beta/IL-6/TNF-alpha axis directly relevant to the BLUE loop IFN-I pathway central to this interferonopathy syndrome, though not disease-specific.
DOI: 10.1016/j.ejmech.2026.119146

Biallelic mutations in SUPV3L1 cause a variable leukodystrophy due to impaired mitochondrial degradosome function (from Neurology/neurogenetics (leukodystrophy))
L. Green; NoΓ©mie Hamilton; M. Elpidorou; R. Maroofian; Maha S. Zaki β€” Research Square 2026
Score: 6/10 | Pathways: cGAS-STING, JAK-STAT, AGS-spectrum, clinical-phenotype, other

Describes a distinct mitochondrial nucleic-acid-sensing disorder (mitochondrial dsRNA degradosome dysfunction) converging on type I interferon activation via dysplastic microglia, mechanistically analogous though not identical to the SAMHD1-driven interferonopathy loop (Blue/Red streams).
DOI: 10.21203/rs.3.rs-4356120/v2

Clinical phenotype and laboratory markers in patients affected by haploinsufficiency of A20 (HA20): a case series from two Italian centres (from Rheumatology/pediatric autoinflammatory disease)
Laura De Nardi; Silvia Federici; Eleonora De Martino; Camilla Celani; Martina Gi β€” RMD Open 2026
Score: 5/10 | Pathways: NF-kB-IKK, clinical-phenotype, AGS-spectrum

A20 (TNFAIP3) haploinsufficiency is a distinct NF-kB-regulatory autoinflammatory disease showing an analogous interferon-signature/NF-kB-driven phenotype with neuropsychiatric comorbidity, offering indirect mechanistic and biomarker parallels to the SAMHD1 interferonopathy-NF-kB axis but no direct SAMHD1 or mitochondrial dNTP data.
DOI: 10.1136/rmdopen-2026-006763

🟒 Low Relevance (Score 3–4)

Potential specialty bridges β€” skim titles

Low-dose radiotherapy remodels the tumor immune microenvironment via the cGAS–STING pathway: mechanisms, challenges, and combination therapy strategies (from Oncology/radiotherapy)
Yongze He; Xianhu Zeng; Qianyi Liu; Linsen Zhou; Ying Tang β€” Molecular Cancer 2026
Score: 4/10 | Pathways: cGAS-STING, NF-kB-IKK, treatment-target

This oncology-focused review discusses cGAS-STING and NF-ΞΊB activation via radiotherapy-induced DNA damage in tumors, mechanistically overlapping with the Blue loop but in a distinct clinical context (cancer immunotherapy) not directly tied to SAMHD1 or the interferon-mitochondrial syndrome.
DOI: 10.1186/s12943-026-02634-5

Orally delivered Perilla frutescens-derived nanovesicles regulate the gut-kidney biointerface to attenuate hyperuricemia-associated renal injury. (from Nephrology/gut-kidney axis nutraceutical delivery)
Yang Zhuohang; Yang Siqi; Ran Yi; Zhang Tangqing; Zhang Fen β€” Colloids and surfaces. B, Biointerfaces 2026
Score: 3/10 | Pathways: urate-NLRP3

The paper touches on the GOLD-stream urate-NLRP3 axis via hyperuricemia-induced renal NLRP3 inflammation, but is a nanovesicle/nephrology-nutraceutical study unrelated to SAMHD1 or the broader interferon-mitochondrial mechanism.
DOI: 10.1016/j.colsurfb.2026.115995

Precision prime editing of TP53 mutations for functional tumor suppression in colorectal cancer. (from Oncology/genome engineering)
Azhar Md; Malviya Rishabha; Chandra Phool; Sridhar Sathvik Belagodu; Shareef Jav β€” Biochemical and biophysical research communications 2026
Score: 3/10 | Pathways: prime-editing

Discusses prime editing technology for TP53 in colorectal cancer, offering only generic technical relevance to gene correction methods rather than SAMHD1 or immune-mitochondrial mechanisms.
DOI: 10.1016/j.bbrc.2026.154311

Oxoisoaporphine Alkaloid Piano-Stool Arene Ruthenium(II) Derivative: A cGAS-STING-Mediated Chemoimmunotherapy Inducer that Acts as a Dual Catalytic Inhibitor of Topoisomerase I/II. (from Medicinal chemistry/oncology drug design)
Liang-Mei Yang; Yuan Lu; Matthew S. Levine; Xueqian Wang; Ya-Qian Shi β€” Journal of the American Chemical Society 2026
Score: 3/10 | Pathways: cGAS-STING

Describes a ruthenium-based chemotherapeutic that activates cGAS-STING for oncologic immunotherapy, sharing a pathway node but with no connection to SAMHD1, mitochondrial dNTP biology, or the family's clinical phenotypes.
DOI: 10.1021/jacs.6c01872

Pathway Coverage This Week

  • cGAS-STING: 4 papers
  • treatment-target: 2 papers
  • AGS-spectrum: 2 papers
  • clinical-phenotype: 2 papers
  • NF-kB-IKK: 2 papers
  • JAK-STAT: 1 papers
  • other: 1 papers
  • urate-NLRP3: 1 papers
  • prime-editing: 1 papers